



Đồng Tháp, ngày 30 tháng 07 năm 2026
Dong Thap, July 30, 2026

Số/No.: 442/2026/TIPHARCO

**CÔNG BỐ THÔNG TIN BẤT THƯỜNG
EXTRAORDINARY INFORMATION DISCLOSURE**

**Kính gửi/To: - Ủy ban Chứng khoán Nhà nước/The State Securities Commission
- Sở Giao dịch Chứng khoán Hà Nội/Ha Noi Stock Exchange**

1. Tên tổ chức/Name of organization: Công ty Cổ phần Dược phẩm Tipharco/Tipharco Pharmaceutical JSC

- Mã chứng khoán/Mã thành viên/ Stock code/ Broker code: DTG
- Địa chỉ/Address: Lô 08, 09 CCN và TTCN Tân Mỹ Chánh, Phường Mỹ Phong, Tỉnh Đồng Tháp, Việt Nam / Lot 08, 09 Tan My Chanh Industrial Park and Industrial Center, My Phong Ward, Dong Thap Province, Vietnam.
- Điện thoại liên hệ/Tel: 0273.3872973 - 0913728988 Fax: 0273.3885040
- E-mail: ir@tipharco.vn

2. Nội dung thông tin công bố/Contents of disclosure:

Công ty Cổ phần Dược phẩm Tipharco (DTG) công bố thông tin như sau:

Tipharco Pharmaceutical JSC ("DTG") announces the following:

Ngày 29/07/2026, Hội đồng quản trị Công ty Cổ phần Dược phẩm Tipharco (DTG) đã ban hành nghị quyết số 18/2026/NQ-HĐQT-DTG về việc thông qua giao dịch với tổ chức có liên quan của Công ty với Công ty TNHH BCG Alliance, tổng giá trị giao dịch phát sinh trong 12 tháng kể từ ngày Hội đồng quản trị thông qua, chỉ được thực hiện trong phạm vi thẩm quyền quyết định của Hội đồng quản trị.

On 29 July 2026, the Board of Directors of Tipharco Pharmaceutical Joint Stock Company (ticker: DTG) issued Resolution No. 18/2026/NQ-HĐQT-DTG approving the related-party transaction between the Company and BCG Alliance Company Limited. The aggregate value of transactions arising within 12 months from the date of the Board of Directors' approval shall be carried out only within the approval authority of the Board of Directors in accordance with applicable laws and the Company's Charter.

3. Thông tin này đã được công bố trên trang thông tin điện tử của Công ty vào ngày 30/07/2026 tại đường dẫn: <https://tipharco.vn/quan-he-co-dong/cong-bo-thong-tin/2026>


This information was published on the company's website on 30/07/2026, as in the link: <https://tipharco.vn/en-US/investor-relations/disclosure/2026-ENG>

Chúng tôi xin cam kết các thông tin công bố trên đây là đúng sự thật và hoàn toàn chịu trách nhiệm trước pháp luật về nội dung các thông tin đã công bố

We hereby certify that the information provided is true and correct and we bear full responsibility to the law.

**CÔNG TY CỔ PHẦN DƯỢC PHẨM TIPHARCO/
TIPHARCO PHARMACEUTICAL JSC**

**NGƯỜI ĐẠI DIỆN THEO PHÁP LUẬT/ *LEGAL*
*REPRESENTATIVE***



LÊ THANH TÙNG



No: 18/2026/NQ-HDQT-DTG

Dong Thap, July 29, 2026

RESOLUTION

Re: Approval of the transactions with the Company's related parties

THE BOARD OF DIRECTORS TIPHARCO PHARMACEUTICAL JOINT STOCK COMPANY

- Pursuant to the Enterprise Law No. 59/2020/QH14 dated June 17, 2020 and the Law amending and supplementing a number of articles of the Enterprise Law No. 76/2025/QH15 dated June 17, 2025 of the National Assembly of the Socialist Republic of Vietnam;
- Pursuant to the Charter of Tipharco Pharmaceutical Joint Stock Company approved by the Board of Directors on August 18, 2025 under the authorization of the General Meeting of Shareholders;
- Pursuant to the Summary Minutes of the Opinion Poll of Board Members No. 18/2026/BB-HĐQT-DTG dated July 29, 2026.

RESOLVES

Article 1. Approval of the transactions with related parties as follows:

- Approve the signing and execution of goods purchase and sale transactions between Tipharco Pharmaceutical Joint Stock Company (seller) and BCG Alliance Limited Company (buyer).
- The total value of transactions arising within 12 months from the date of approval by the Board of Directors shall only be carried out within the scope of the Board of Directors' decision-making authority as stipulated by law and the Company's Charter.
- The signing and execution of the above-mentioned transactions shall be valid for 12 months from the date of approval by the Board of Directors. After this period, further transactions may only be carried out with the approval of the competent authority as stipulated by law and the Company's Charter. If the General Meeting of Shareholders approves the plan for transactions with related parties for the following year, the execution of the transaction shall comply with the Resolution of the General Meeting of Shareholders.

Article 2. The Chief Executive Officer is authorized to proactively negotiate and decide on specific commercial terms; sign, amend, supplement, extend, terminate, and liquidate contracts, contract addendums, and related documents to implement transactions approved by the Board of Directors; and ensure compliance with

the law, the Company's Charter, and the scope of authority approved by the Board of Directors.

Article 3. The Management Board is responsible for monitoring and controlling transactions arising during the implementation process; ensuring that the transaction implementation complies with the scope approved by the Board of Directors; disclosing information (if obligations arise) and reporting to the Board of Directors and the Supervisory Board as required by law or when requested.

Article 4. This Resolution takes effect from the date of signing. Members of the Board of Directors, the Management Board of the Company, the Divisions, Departments, Sections and related individuals are responsible for implementing this Resolution.

Recipients:

- As Article 4
- Supervisory Board
- Filing: BOD

ON BEHALF OF THE BOARD OF DIRECTORS

CHAIRMAN



Tran Ngoc Tuan